Related Experiment Videos
Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed?
Xingchang Wei1, Charles R G Guttmann, Simon K Warfield
1Seaman Family MR Research Center, Departments of Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 26, 2004
Summary
This study establishes reliable thresholds for tracking changes in multiple sclerosis (MS) patients using MRI. These findings help neurologists distinguish true disease progression from measurement error in individual patient assessments.
Area of Science:
- Neurology
- Medical Imaging
- Biostatistics
Background:
- Magnetic resonance imaging (MRI)-derived measurements are crucial for assessing multiple sclerosis (MS) progression in clinical trials.
- Interpreting subtle changes in individual MS patients in daily clinical practice remains challenging due to measurement variability.
Purpose of the Study:
- To quantify the measurement error of an automated brain tissue quantification algorithm for MRI.
- To establish statistically significant change thresholds for T2 lesion volume and brain atrophy in individual MS patients.
Main Methods:
- Twenty MS patients underwent two MRI scans within 30 minutes.
- Automated algorithms quantified brain tissue volumes and estimated brain parenchymal fraction for atrophy.
- Measurement error thresholds were determined for T2 lesion burden and brain parenchymal fraction.
Main Results:
- A change of 0.65 mL in T2 lesion burden indicates statistically significant change beyond measurement error with 95% certainty.
- A change of 0.0056 in brain parenchymal fraction signifies statistically significant brain atrophy beyond measurement error with 95% certainty.
- Changes below these thresholds are attributable to measurement variability alone.
Conclusions:
- The study provides critical reference values for neurologists to interpret individual patient MRI data in MS.
- These thresholds enhance the clinical utility of MRI in monitoring MS progression at the individual patient level.
- Distinguishing true changes from measurement error improves patient management and therapeutic trial interpretation.